Document:

EXHIBIT 4.20

                          STOCK SUBSCRIPTION AGREEMENT

ADVENTRX Pharmaceuticals, Inc.
9948 Hibert Street, Suite 100

San Diego, CA  92131

This letter represents an agreement (this "AGREEMENT") between the undersigned
(the "INVESTOR") and ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the
"COMPANY"), related to the Investor's offer to purchase shares of the Company's
Common Stock, par value $0.001 per share ("COMMON STOCK").

1. SUBSCRIPTION. Subject to the terms and conditions hereof, the Investor hereby
irrevocably subscribes for and agrees to purchase shares of Common Stock (the
"SUBSCRIPTION") as follows:

      Investor's name: [SEE ATTACHED SCHEDULE]

                      (Exact name as it should appear on the stock certificate.)

      Price per share of Common Stock (the "PURCHASE PRICE"): One Dollar ($1.00)

      Number of shares of Common Stock: [SEE ATTACHED SCHEDULE]

      Total Purchase Price: [SEE ATTACHED SCHEDULE]

In consideration of the issuance of the number of shares of Common Stock listed
above (the "SHARES"), the Investor tenders herewith a wire transfer to the
account of the Company transmitted pursuant to the wire instructions attached
hereto as Exhibit A in the aggregate amount of the Total Purchase Price listed
above.

2. ACCEPTANCE OF SUBSCRIPTION. The Investor understands and agrees that this
Subscription is made subject to the unconditional right of the Company to reject
this Subscription, in whole or in part, in its sole and absolute discretion.
This Agreement shall become effective upon acceptance by the Company (the
"ACCEPTANCE Date"). Any interest earned on funds sent to the Company pursuant to
Section 1 hereof will be for the account of the Company if the Subscription is
accepted. This Subscription is made subject to the terms and conditions set
forth below.

3. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.

      (A) EXEMPT TRANSACTION; UNREGISTERED SHARES. The Investor understands that
the Shares are being offered and sold under one or more exemptions from
registration provided for under the Securities Act of 1933, as amended (the
"SECURITIES ACT"), and that the Company's reliance upon such exemptions is
predicated, in part, upon the Investor's representations and warranties set
forth in this Agreement. The Investor acknowledges that it is purchasing the
Shares without being offered or furnished any offering literature or prospectus.
The Investor understands that neither the United States Securities and Exchange
Commission, nor any governmental agency charged with the administration of the
securities laws of any state nor any other governmental agency has passed upon
or reviewed the merits or qualifications of, or recommended or approved the
offer and sale of the Shares pursuant to the terms of this Agreement.

                                       1
<PAGE>

      (B) INVESTMENT INTENT; ACCREDITATION; AUTHORITY. The Investor is acquiring
the Shares for investment for the Investor's own account, not as nominee or
agent, for investment and not with a view to, or for resale in connection with,
any distribution or public offering thereof within the meaning of the Securities
Act. The Investor is an "accredited investor" within the meaning of the
Securities Act. The Investor has the full right, power, authority and capacity
to enter into and perform this Agreement, the terms of this Agreement constitute
valid and binding obligations of the Investor enforceable in accordance with
their terms, except as the same may be limited by equitable principles and by
bankruptcy, insolvency, moratorium, and other laws of general application
affecting the enforcement of creditors' rights.

      (C) KNOWLEDGE AND EXPERIENCE. The Investor (i) has such knowledge and
experience in financial and business matters as to be capable of evaluating the
merits and risks of the Investor's prospective investment in the Shares; (ii)
has the ability to bear the economic risks of the Investor's prospective
investment; (iii) has been furnished with and has had access to such information
as the Investor has considered necessary to make a determination as to the
purchase of the Shares together with such additional information as is necessary
to verify the accuracy of the information supplied; and (iv) has had all
questions which have been asked by Investor satisfactorily answered by the
Company.

      (D) RESTRICTED SECURITIES. The Investor understands that the Shares are
"restricted securities" as such term is defined in Rule 144 of Regulation D
promulgated under the Securities Act ("RULE 144") and must be held indefinitely
unless they are subsequently registered under applicable state and federal
Securities laws or an exemption from such registration is available. The
Investor understands that he, she or it may resell the Shares pursuant to Rule
144 only after the satisfaction of certain requirements, including the
requirement that the Shares be held for at least one year prior to resale.

      (E) NO OBLIGATION TO REGISTER SHARES. The Investor further acknowledges
and understands that, except as provided in Section 7 of this Agreement, the
Company is under no obligation to register the Shares. The Investor understands
that the certificate evidencing the Shares will be imprinted with a legend which
prohibits the transfer of the Shares unless they are registered or such
registration is not required in the opinion of counsel for the Company.

      (F) INVESTOR QUESTIONNAIRE. The Investor agrees to complete, execute and
deliver to the Company with this executed Agreement a copy of the Investor
Suitability Questionnaire attached hereto as Exhibit B, the terms of which are
incorporated herein.

      (G) FOREIGN INVESTOR REPRESENTATION. If the Investor is not a "U.S.
person" (as such term is defined in Rule 902(k) of Regulation S promulgated
under the Securities Act), such Investor hereby represents that it has satisfied
itself as to the full observance of the laws of its jurisdiction in connection
with any invitation to subscribe for the Shares or any use of this Agreement,
including (i) the legal requirements within its jurisdiction for the purchase of
the Shares, (ii) any foreign exchange restrictions applicable to such purchase,
(iii) any governmental or other consents that may need to be obtained, and (iv)
the income tax and other tax consequences, if any, that may be relevant to the
purchase, holding, redemption, sale or transfer of the Shares. Such Investor's
subscription and payment for, and its continued beneficial ownership of the
Shares, will not violate any applicable securities or other laws of its
jurisdiction.

                                       2
<PAGE>

      (H) DOMICILE. The Investor is a bona fide resident and domiciliary (not a
temporary or transient resident) of the state indicated on Exhibit B hereto and
he, she or it has no present intention of becoming a resident of any other state
or jurisdiction.

      (I) NO NEED FOR LIQUIDITY. The Investor's aggregate holding of securities
that are "restricted securities" or otherwise not readily marketable is not
excessive in view of the Investor's net worth and financial circumstances and
the purchase of the Shares will not cause such commitment to become excessive.

      (J) INDEPENDENT ADVICE. The Investor understands that the Company urges
the Investor to seek independent advice from professional advisors relating to
the suitability for the Investor of an investment in the Company in view of the
Investor's overall financial needs and with respect to legal and tax
implications of such an investment.

4. RELIANCE. The Investor understands that the Company may rely on the foregoing
representations and warranties in determining whether to accept this
Subscription. If for any reason any representations and warranties are no longer
true and accurate prior to the Acceptance Date, the Investor will give the
Company prompt written notice of the inaccuracy. By signing below, the Investor
represents that the Investor has read and confirmed the truth and accuracy of
each of the foregoing representations and warranties.

5. INDEMNIFICATION. The Investor agrees to indemnify and hold harmless the
Company and each of its directors, officers, agents and affiliates from and
against any and all loss, damage or liability due to or arising out of a breach
of any representation, warranty or covenant of the undersigned contained in this
Agreement.

6. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS.

      (A) LEGEND. The stock certificate representing the Shares shall bear the
following legend or similar legend (as well as any legends required by
applicable state and federal corporate and securities laws):

      THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR
      OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED
      UNDER THE ACT OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE
      SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
      TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

                                       3
<PAGE>

      (B) REMOVAL OF LEGEND AND TRANSFER RESTRICTIONS. Any legend endorsed on a
certificate pursuant to this Section 6 and the stop transfer instructions with
respect to such legended Shares shall be removed, and the Company shall issue a
certificate without such legend to the holder of such Shares if such Shares are
registered under the Securities Act, and a prospectus meeting the requirements
of Section 10 of the Securities Act is available or if such holder satisfies the
requirements of Rule 144(k) or if such holder provides the Company with an
opinion of counsel for such holder of the Securities, reasonably satisfactory to
the Company, to the effect that a sale, transfer or assignment of such Shares
may be made without registration.

7. REGISTRATION RIGHTS.

      (A) PIGGY-BACK RIGHTS. If (but without any obligation to do so) the
Company proposes to register any of shares of Common Stock in connection with
any offering of shares of Common Stock solely for cash pursuant to a
registration statement under the Securities Act, other than a registration
solely in connection with a transaction under Rule 145 promulgated under the
Securities Act (a "PUBLIC OFFERING"), the Company shall promptly give the
Investor written notice of such registration, at least 10 business days prior to
the filing of any registration statement under the Securities Act. Upon the
written request of the Investor given within 5 business days after delivery of
such written notice by the Company, the Company shall, subject to the provisions
of Section 7(b) below, use its best efforts to cause to be registered under the
Securities Act all of the Shares that the Investor has requested to be
registered.

      (B) UNDERWRITING. If the registration statement under which the Company
gives notice under this Section 7 is for an underwritten Public Offering, the
Company shall so advise the Investor. The right of the Investor to registration
pursuant to Section 7(a) above shall be conditioned upon the Investor's
participation in such underwriting and the inclusion of the Shares in the
underwriting to the extent provided herein. The Investor shall (together with
the Company and any other holders of Company securities distributing their
securities through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for underwriting by
the Company. Notwithstanding any other provision of this Section 7, if the
underwriter determines that marketing factors require a limitation of the number
of shares to be underwritten, the underwriter may exclude some or all of the
Shares from such registration and underwriting.

      (C) FURNISH INFORMATION. It shall be a condition to the Company's
obligations to take any action under this Section 7 that the Investor shall
furnish to the Company such information regarding itself, the Shares, and the
intended method of disposition of such securities as shall be required to effect
the registration of their Shares. In that connection, each selling Investor
shall be required to represent to the Company that all such information which is
given is both complete and accurate in all material respects when made.

      (D) DELAY OF REGISTRATION. The Investor shall have no right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 7.

                                       4
<PAGE>

      (E) TERMINATION OF REGISTRATION RIGHTS. The Company shall have no
obligation to register the Shares pursuant to this Section 7 with respect to any
request or requests made by any Investor on or after that date which is one year
after the Acceptance Date.

8. PRICE PROTECTION. If at any time after the Acceptance Date and before the
date that is one year after the Acceptance Date, the Company issues or sells any
shares of its Common Stock (other than Excluded Shares (as that term is defined
below)) for a consideration per share (the "DILUTIVE PRICE") less than the
Purchase Price, then the Company will issue to the Investor a number of shares,
if positive, of Common Stock determined by the following formula:

     X  =  (A / B) -  (C + D)

     Where:       X    =   the number of shares of Common Stock to be issued to
                           the Investor, rounded to the nearest whole number;

                  A    =   the Total Purchase Price;

                  B    =   the Dilutive Price;

                  C    =   the number of Shares held by the Investor; and

                  D    =   the aggregate number of shares of
                           Common Stock issued to the Investor
                           pursuant to this Section 8 prior to the
                           date of such determination.

     Notwithstanding the foregoing, in no event will the Company be obligated to
     issue to the Investor in the aggregate a number of shares of Common Stock
     pursuant to this Section 8 in excess of the number determined by the
     following formula:

                       X  =  (A / B) -  C

     Where:       X    =   the maximum aggregate number of shares of Common
                           Stock issuable to the Investor pursuant to Section 8,
                           rounded to the nearest whole number;

                  A    =   the Total Purchase Price;

                  B    =   Fifty Cents ($0.50); and

                  C    =   the number of Shares initially
                           purchased by the Investor pursuant to
                           the terms of this Agreement.

                                       5
<PAGE>

     For purposes of this Agreement, the term "EXCLUDED SHARES" means: (i)
     shares of Common Stock issuable or issued after the Acceptance Date to
     officers, employees, consultants or directors of the Company directly or
     pursuant to a stock purchase, stock option, restricted stock or other
     written compensation plan or agreement approved by the Board of Directors
     of the Company (the "BOARD"); (ii) shares of Common Stock issued or
     issuable after the Acceptance Date, primarily for non-equity financing
     purposes and as approved by the Board, to financial institutions or lessors
     in connection with commercial credit arrangements, equipment financings or
     similar transactions or to vendors of goods or services or customers; (iii)
     shares of Common Stock issuable upon (a) exercise of outstanding warrants,
     options, notes or other rights to acquire securities of the Company, (b)
     conversion of outstanding shares of the Company's Preferred Stock, par
     value $0.01 per share or (c) exchange of outstanding promissory notes
     issued by the Company; (iv) capital stock or warrants or options to
     purchase capital stock issued in connection with bona fide acquisitions,
     mergers or similar transactions, the terms of which are approved by the
     Board; or (v) shares of Common Stock issued or issuable by way of dividend
     or other distribution on Excluded Shares.

9. MISCELLANEOUS.

      (A) GOVERNING LAW. This Agreement, all acts and transactions pursuant
hereto and the rights and obligations of the parties hereto shall be governed,
construed and interpreted in accordance with the laws of the state of
California, without giving effect to principles of choice of law.

      (B) JURISDICTION AND VENUE. Any legal action or other legal proceeding
relating to this Agreement or the enforcement of any provision of this Agreement
shall be brought or otherwise commenced in any state or federal court located in
the county of San Diego, California. Each party to this Agreement: (i) expressly
and irrevocably consents and submits to the jurisdiction of each state and
federal court located in the county of San Diego, California and each appellate
court located in the state of California, in connection with any such legal
proceeding; (ii) agrees that each state and federal court located in the county
of San Diego, California shall be deemed to be a convenient forum; and (iii)
agrees not to assert, by way of motion, as a defense or otherwise, in any such
legal proceeding commenced in any state or federal court located in the county
of San Diego, California any claim that such party is not subject personally to
the jurisdiction of such court, that such legal proceeding has been brought in
an inconvenient forum, that the venue of such proceeding is improper or that
this Agreement or the subject matter of this Agreement may not be enforced in or
by such court.

      (C) ENTIRE AGREEMENT. This Agreement embodies the entire agreement and
understanding between the parties hereto with respect to the subject matter
hereof and supersedes all prior oral or written agreements and understandings
relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement of any kind not expressly set forth in this Agreement
shall affect, or be used to interpret, change or restrict, the express terms and
provisions of this Agreement.

      (D) NOTICES. All notices and other communications hereunder shall be in
writing and shall be given (and shall be deemed to have been duly given upon
receipt) by delivery in person or facsimile transmission (received at the
facsimile machine to which it is transmitted prior to 5:00 p.m., local time, on
a business day in the state of California, for the party to which it is sent),
by courier or express delivery service or by registered or certified mail
(postage prepaid, return receipt requested) to the respective parties at the
following addresses (or at such other address for a party as shall be specified
in a notice given in accordance with this Section):

                                       6
<PAGE>

     if to the Company:                          ADVENTRX Pharmaceuticals, Inc.
                                                 9948 Hibert Street, Suite 100
                                                 San Diego, CA  92131
                                                 Attention: Nicholas J. Virca
                                                 Facsimile: (858) 271-9678

     with a copy to (not to constitute notice):  Bingham McCutchen LLP
                                                 3 Embarcadero Center
                                                 San Francisco, CA  94111-4067
                                                 Attention: Francis W. Sarena
                                                 Facsimile: (415) 393-2286

     if to the Investor:                         To the address set forth in
                                                 Exhibit B hereto.

      (E) MODIFICATIONS AND AMENDMENTS. The terms and provisions of this
Agreement may be modified or amended only by written agreement executed by the
parties hereto.

      (F) WAIVERS AND CONSENTS. The terms and provisions of this Agreement may
be waived, or consent for the departure therefrom granted, only by written
document executed by the party entitled to the benefits of such terms or
provisions. No such waiver or consent shall be deemed to be or shall constitute
a waiver or consent with respect to any other terms or provisions of this
Agreement, whether or not similar. Each such waiver or consent shall be
effective only in the specific instance and for the purpose for which it was
given, and shall not constitute a continuing waiver or consent.

      (G) ASSIGNMENT. This Agreement may not be transferred or assigned without
the prior written consent of the Company and any such transfer or assignment
shall be made only in accordance with applicable laws and any such consent.

      (H) SEVERABILITY. In the event that any court of competent jurisdiction
shall determine that any provision, or any portion thereof, contained in this
Agreement shall be unenforceable in any respect, then such provision shall be
deemed limited to the extent that such court deems it enforceable, and as so
limited shall remain in full force and effect. In the event that such court
shall deem any such provision, or portion thereof, wholly unenforceable, the
remaining provisions of this Agreement shall nevertheless remain in full force
and effect.

      (I) INTERPRETATION. The parties hereto acknowledge and agree that: (i)
each party and such party's counsel has reviewed the terms and provisions of
this Agreement; (ii) the rule of construction to the effect that any ambiguities
are resolved against the drafting party shall not be employed in the
interpretation of this Agreement; and (iii) the terms and provisions of this
Agreement shall be construed fairly as to the parties hereto and not in favor of
or against any party, regardless of which party was generally responsible for
the preparation of this Agreement. Whenever used herein, the singular number
shall include the plural, the plural shall include the singular, the use of any
gender shall include all persons.

      (J) HEADINGS AND CAPTIONS. The headings and captions of the various
subdivisions of this Agreement are for convenience of reference only and shall
in no way modify, or affect the meaning or construction of any of the terms or
provisions hereof.

                                       7
<PAGE>

      (K) NO WAIVER OF RIGHTS, POWERS AND REMEDIES. No failure or delay by a
party hereto in exercising any right, power or remedy under this Agreement, and
no course of dealing between the parties hereto, shall operate as a waiver of
any such right, power or remedy of the party. No single or partial exercise of
any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, power or
remedy, shall preclude such party from any other or further exercise thereof or
the exercise of any other right, power or remedy hereunder. The election of any
remedy by a party hereto shall not constitute a waiver of the right of such
party to pursue other available remedies. No notice to or demand on a party not
expressly required under this Agreement shall entitle the party receiving such
notice or demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such
notice or demand to any other or further action in any circumstances without
such notice or demand.

      (L) SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All representations and
warranties made by the parties hereto in this Agreement, shall survive (i) the
execution and delivery hereof, (ii) any investigations made by or on behalf of
the parties and (iii) the closing of the transaction contemplated hereby.

      (M) EXPENSES. Each of the parties hereto shall pay its own fees and
expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Agreement and the transactions
contemplated hereby whether or not the transactions contemplated hereby are
consummated.

      (N) FACSIMILE DELIVERY. Any signature page delivered by electronic
facsimile shall be binding to the same extent as an original signature page,
with regard to any agreement subject to the terms hereof or any amendment
thereto. Any party who delivers such a signature page agrees to later deliver an
original counterpart to the other party upon request.

      IN WITNESS WHEREOF, the undersigned has executed this Agreement this ___
day of ______________, 2003.

                                    INVESTOR:

                                    By: [SEE ATTACHED SCHEDULE]

                                           (signature)

                                    Name:_______________________________________
                                              (please print)

                                    Title:______________________________________
                                             (if applicable)

ADVENTRX Pharmaceuticals, Inc. hereby accepts the foregoing Subscription subject
to the terms and conditions hereof as of _________ __, 2003

ADVENTRX PHARMACEUTICALS, INC.

By:   /s/ Nicholas J. Virca
      ---------------------
      Nicholas J. Virca, Chief Executive Officer

                                       8

<PAGE>

                                    EXHIBIT A

                                WIRE INSTRUCTIONS

The following information is provided to assist you in routing wire transfers TO
the account of ADVENTRX Pharmaceuticals, Inc. at Silicon Valley Bank in the most
expeditious manner.

For all incoming FOREIGN CURRENCY wires, please contact Silicon Valley Bank's
INTERNATIONAL DEPARTMENT AT (408) 654-7774 for settlement instructions.

DOMESTIC WIRE TRANSFER:

Instruct the paying financial institution or the payor to route all domestic
wire transfers via FEDWIRE to the following ABA number:

         TO:                                   SIL VLY BK SJ

         ROUTING & TRANSIT #:                  121140399

         FOR CREDIT OF:                        ADVENTRX Pharmaceuticals, Inc.

         CREDIT ACCOUNT #:                     3300340922

         BY ORDER OF:                          [NAME OF SENDER]

INTERNATIONAL WIRE TRANSFER:

Instruct the paying financial institution to advise their U.S. correspondent to
pay as follows:

         PAY TO:                                FC - SILICON VALLEY BANK

                                                3003 TASMAN DRIVE

                                                SANTA CLARA, CA  95054, USA

         ROUTING & TRANSIT #:                   \\FW121140399

         SWIFT CODE:                            SVBKUS6S

         FOR CREDIT OF:                         ADVENTRX Pharmaceuticals, Inc.

         FINAL CREDIT ACCOUNT #:                FNC - 3300340922

         BY ORDER OF:                           [NAME OF SENDER]

IMPORTANT!!!!

Wire instructions MUST designate the FULL TEN DIGIT ACCOUNT NUMBER listed above.
Wires received by Silicon Valley Bank with INCOMPLETE or INVALID ACCOUNT NUMBERS
may be delayed and could possibly require return to the sending bank due to new
regulations.

                                       9
<PAGE>

                                    EXHIBIT B

                       INVESTOR SUITABILITY QUESTIONNAIRE

                 ADVENTRX PHARMACEUTICALS, INC. (THE "COMPANY")
                (All information will be treated confidentially)

                          I. INDIVIDUAL INVESTORS ONLY

A.    PERSONAL INFORMATION

         Name: _________________________________________________________________
                    (Exact name as it should appear on stock certificate.)

         Residence Address: ____________________________________________________

         _______________________________________________________________________

         _______________________________________________________________________

         Home Telephone Number: ________________________________________________

         Fax Telephone Number: _________________________________________________

         Email Address: ________________________________________________________

         Social Security Number: _______________________________________________

B.    DELIVERY INFORMATION (Applicable only if different than residence.)

         Name of Institution or Destination: ___________________________________

         Contact Name: _________________________________________________________

         Delivery Address: _____________________________________________________

         Account Reference (if applicable): ____________________________________

         Contact Telephone Number: _____________________________________________

         Contact Fax Telephone Number: _________________________________________

         Contact Email Address: ________________________________________________

                                      B-1
<PAGE>

C.       EMPLOYMENT INFORMATION

         Occupation: ___________________________________________________________

         Number of Years: ______________________________________________________

         Present Employer: _____________________________________________________

         Position/Title: _______________________________________________________

         Business Address: _____________________________________________________

         Business Telephone: ___________________________________________________

D.       RESIDENT INFORMATION

         Set forth in the space provided below the state(s)/country(ies) in
         which you have maintained your principal residence during the past
         three years and the date during which you resided in each
         state/country.

         Are you registered to vote in, or do you have a driver's license issued
         by, or do you maintain a residence in any other state? If yes, in which
         state(s)?

                  Yes  _____                                  No  _____

E.       INCOME

         Do you reasonably expect either your own income from all sources during
         the current year to exceed $200,000 or the joint income of you and your
         spouse (if married) from all sources during the current year to exceed
         $300,000?

                  Yes  _____                                  No  _____

                  If not, please specify the amount:

         What percentage of your income as shown above is anticipated to be
         derived form sources other than salary?

                                      B-2

<PAGE>

         Was either your yearly income from all sources during each of the last
         two years in excess of $200,000 or was the joint income of you and your
         spouse (if married) from all sources during each of such years in
         excess of $300,000?

                  Yes  _____                                  No  _____

                  If no, please specify the amount for:

                  Last Year: ___________________________________________________

                  Year Before Last: ____________________________________________

F.       NET WORTH

         Will your net worth* as of the date you purchase securities of the
         Company, together with the net worth of your spouse, be in excess of
         $1,000,000?

                  Yes  _____                                  No  _____

         If not, please specify amount:

         * As used in this questionnaire the term "net worth" means the amount
         by which total assets exceed total liabilities. In computing net worth
         for purposes of this Item 5, you should value your principal residence
         at cost, including cost of improvements, or at that value recently
         appraised by an institutional lender making a secured loan or otherwise
         by a certified appraiser, net of encumbrances.

G.       EDUCATION

         Please describe your educational background and degrees obtained, if
any.

         _______________________________________________________________________

         _______________________________________________________________________

H.       AFFILIATION

         If you have any pre-existing personal or business relationship with the
         Company or any of its officers, directors or controlling persons,
         please describe the nature and duration of such relationship.

         _______________________________________________________________________

         _______________________________________________________________________

                                      B-3

<PAGE>

I.       BUSINESS AND FINANCIAL EXPERIENCE

         Please describe in reasonable detail the nature and extent of your
         business, financial and investment experience which you believe give
         you the capacity to evaluate the merits and risks of the proposed
         investment and the capacity to protect your interests.

         _______________________________________________________________________

         _______________________________________________________________________

         _______________________________________________________________________

         Are you purchasing the securities offered for your own account and for
investment purposes only?

                  Yes  _____                                  No  _____

                  If no, please state for whom you are investing and/or the
reason for investing.

         _______________________________________________________________________

         _______________________________________________________________________

         _______________________________________________________________________

                                      B-4

<PAGE>

                            II. ENTITY INVESTORS ONLY

A.       ENTITY NAME AND CONTACT INFORMATION

         Name: _________________________________________________________________
                    (Exact name as it should appear on stock certificate.)

         Name of Institution or Destination: ___________________________________

                                  (Include if different from stock certificate.)

         Address: ______________________________________________________________

         _______________________________________________________________________

         _______________________________________________________________________

         Account Reference (if applicable): ____________________________________

         Tax Identification Number (if applicable): ____________________________

         Contact Name: _________________________________________________________

         Contact Telephone Number: _____________________________________________

         Contact Fax Number: ___________________________________________________

         Contact Email Address: ________________________________________________

B.       GENERAL INFORMATION

         Under the laws of what jurisdiction was the Investor formed? __________

         Was the Investor formed for the purpose of investing in the securities
being offered?

                  Yes _____         No _____

         Set forth in the space provided below the (i) state(s), if any, in the
         United States in which you maintained your principal office during the
         past two years and the dates during which you maintained your office in
         each state, (ii) the state(s), if any, in which you are incorporated or
         otherwise organized, and (iii) the state(s), if any, in which you still
         pay income taxes:

         _______________________________________________________________________

         _______________________________________________________________________

                                      B-5
<PAGE>

C.       ACCREDITED INVESTOR INFORMATION

         Is the Investor a national bank or a banking institution organized
         under the laws of any state or any territory of the United States or
         the District of Columbia?

                  Yes _____         No _____

         Is the Investor a savings and loan association, building and loan
         association, cooperative bank, homestead association, or similar
         institution, which is supervised and examined by any state or federal
         authority having supervision over such institution?

                  Yes _____         No _____

         Is the Investor a broker or dealer registered pursuant to Section 15 of
         the Securities Exchange Act of 1934?

                  Yes _____         No _____

         Is the Investor a company (i) whose primary and predominant business is
         underwriting insurance and subject to the supervision by a regulatory
         agency under the laws of any state or territory, or (ii) registered as
         an investment company under the Investment Company Act of 1940, or
         (iii) a Small Business Investment Company licensed by the U.S. Small
         Business Administration?

                  Yes _____         No _____

         Is the Investor a "business development company" within the meaning of
         the Investment Company Act of 1940 or the Investment Advisers Act of
         1940?

                  Yes _____         No _____

         Is the Investor an employee benefit plan under the Employee Retirement
         Income Security Act of 1974 (a "PLAN") with assets in excess of
         $5,000,000?

                  Yes _____         No _____

                  If the Investor is such a Plan, but if the Plan's total assets
                  do not exceed $5,000,000, are investment decisions for the
                  Plan made by a bank, savings and loan association, insurance
                  company or registered investment adviser acting as fiduciary?
                  (If yes, please specify the name of the fiduciary.)

                       Yes _____         No _____

                  Name of Fiduciary:____________________________________________

                  If the Investor is a self-directed Plan, but if the Plan's
                  total assets do not exceed $5,000,000, are investment
                  decisions made solely by persons or entities that can answer
                  yes to one or more of the questions under paragraphs (b) - (e)
                  of Item 1, or (c) - (k) under this Item 2? (If yes, please
                  specify the applicable Item and Paragraph.)

                                      B-6
<PAGE>

                       Yes _____         No _____

                       Item and Paragraph:  ___________

         Is the Investor (A)(i) a tax exempt organization which is qualified
         under Section 501(c)(3) of the Internal Revenue Code of 1986 as
         amended, or (ii) a corporation, or (iii) a Massachusetts or similar
         business trust, or (iv) a partnership, not formed for the specific
         purpose of acquiring the securities offered, and (B) which has assets
         in excess of $5,000,000?

                  Yes _____         No _____

         Is the Investor a trust, with total assets in excess of $5,000,000, not
         formed for the specific purpose of acquiring the securities offered,
         whose purchase is directed by a person who has such knowledge and
         experience in financial and business matters that he is capable of
         evaluating the merits and risks of the prospective investment?

                  Yes _____         No _____

                  If yes, please attach a memorandum describing such person's
                  educational background, professional memberships or licenses,
                  current employment, principal business and professional
                  activities during the last five years, and experience as an
                  investor in securities. Include any additional information
                  evidencing that such person has sufficient knowledge and
                  experience in financial matters that such person would be
                  capable of evaluating the merits and risks of investing in the
                  securities being offered.

         Is the Investor an entity in which all of the equity owners are persons
         who are either (i) entities described in paragraphs (c) through (j)
         above; (ii) persons whose net worth, or joint net worth with their
         spouses, exceeds $1,000,000; (iii) persons whose income without regard
         to that of their spouses exceeded $200,000, or whose joint income with
         their spouses exceeded $300,000, in each of the last two years and who
         reasonably expect such person income to exceed $200,000 or such joint
         income to exceed $300,000 this year; or (iv) persons who are brokers or
         dealers registered pursuant to Section 15 of the Securities Exchange
         Act of 1934?

                  Yes _____         No _____

                  If an equity owner is an entity described in paragraphs (h) or
                  (j) under this Item 3, please provide the information required
                  by such paragraph.

                                      B-7
<PAGE>

      The above information has been requested by the Company and will be used
solely to confirm that the Company is complying with certain securities
regulations. In furnishing the above information, the undersigned acknowledges
that the Company will be relying thereon in assessing the requirements of the
Securities Act of 1933, as amended, and other applicable securities laws.

      The information contained in this questionnaire is true and complete, and
the undersigned understands that the Company and its counsel will rely on such
information for the purpose of complying with all applicable securities laws, as
discussed above. The undersigned agrees to notify the Company promptly of any
change in the foregoing information which may occur prior to any purchase by the
undersigned of stock from the Company.

Date: ____________________

INDIVIDUAL INVESTOR:                                ENTITY INVESTOR:

By: [SEE ATTACHED SCHEDULE]                         By:  [SEE ATTACHED SCHEDULE]
           (signature)                                         (signature)

Name: __________________                          Name: ________________________
        (please print)                                        (please print)

                                                 Title: ________________________
                                                              (please print)

                                      B-8
<PAGE>

<TABLE>
<CAPTION>

                              SCHEDULE OF INVESTORS

      ADVENTRX Pharmaceuticals, Inc. entered into this form of Stock
Subscription Agreement with each of the persons listed below on the dates set
forth below for the purchase of the number of shares of Common Stock listed
opposite such person's name below.

INVESTOR                                                                                       DATE         SHARES
--------------------------------------------------------------------------------------------------------------------
<S>                                                                                          <C>            <C>
Peter J. and Elaine Chortek, Trustees of the Peter J. and Elaine Chortek Restarted           7/14/2003       50,000
Family Trust, Dated January 24, 1994 as Amended and restarted
--------------------------------------------------------------------------------------------------------------------
John R. and Marjorie B. Brown                                                                7/15/2003        2,000
--------------------------------------------------------------------------------------------------------------------
David and Jennifer Brown                                                                     7/15/2003          500
--------------------------------------------------------------------------------------------------------------------
Elaine Dines                                                                                  8/6/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Dannie King                                                                                   8/6/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Craig Langweiler                                                                              8/7/2003        3,000
--------------------------------------------------------------------------------------------------------------------
Benjamin Partners Savings Plan FBO Jeffrey Benison                                            8/8/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Robert A. Melnick                                                                             8/8/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Emanuel Peluso                                                                                8/8/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Sandi Yurichuk                                                                                8/9/2003       25,000
--------------------------------------------------------------------------------------------------------------------
William B. Newman                                                                            8/10/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Clariden Investments Ltd.                                                                    9/12/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Mark Eugene Reaman                                                                           9/26/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Jurg Fluck                                                                                   8/11/2003        9,000
--------------------------------------------------------------------------------------------------------------------
Haywood Securities Inc in Trust for Bridge Finance Ltd.                                      8/11/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Roland Hartman                                                                               8/11/2003       20,000
--------------------------------------------------------------------------------------------------------------------
David W. Penney & Sarah B. McAllister                                                        8/12/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Schroder & Co Bank AG                                                                        8/12/2003      150,000
--------------------------------------------------------------------------------------------------------------------
James Ladner                                                                                 8/13/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Deborah Young, M.D. APC Employees Retirement Trust Y/A DTD 4/2/91                            8/14/2003       10,000
--------------------------------------------------------------------------------------------------------------------
BSI-New Biomedical Frontier (Sicav)                                                          8/14/2003      500,000
--------------------------------------------------------------------------------------------------------------------
Paul Mezei                                                                                   8/15/2003        2,000
--------------------------------------------------------------------------------------------------------------------
Michael Kooper                                                                               8/16/2003       50,000
--------------------------------------------------------------------------------------------------------------------
John J. Kissane                                                                              8/18/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Michael Elconin                                                                              8/19/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Ball Family Trust (Edward D. Ball and Susan E. Ball, Trustees)                               8/19/2003      100,000
--------------------------------------------------------------------------------------------------------------------
Brian M. Herman                                                                              8/19/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Sean M. Callahan                                                                             8/20/2003       15,000
--------------------------------------------------------------------------------------------------------------------
Mark A. Ford                                                                                 8/22/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Robert J. Neborsky, MD, Inc.                                                                 8/22/2003      125,000
Combination Retirement Trust U/T/A 11/30/82
--------------------------------------------------------------------------------------------------------------------
Michael M. Goldberg                                                                          8/22/2003       20,000
--------------------------------------------------------------------------------------------------------------------
SDS Merchant Fund, L.P.                                                                      8/25/2003      250,000
--------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-9
<PAGE>

<TABLE>
<CAPTION>

INVESTOR                                                                                       DATE         SHARES
--------------------------------------------------------------------------------------------------------------------

<S>                                                                                          <C>           <C>
Bullbear Capital Partners, LLC                                                               8/25/2003      125,000
--------------------------------------------------------------------------------------------------------------------
Jeff Hermanson                                                                               8/26/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Deborah Melnick                                                                              8/28/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Jay S. and Gabrielle Kunin                                                                   8/28/2003       15,000
--------------------------------------------------------------------------------------------------------------------
Charles and Leslie Close                                                                     8/29/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Eric T. Singer                                                                                9/2/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Botka-Liu Family Revocable Trust, Dated 8/10/2000                                             9/3/2003       20,000
--------------------------------------------------------------------------------------------------------------------
Gene Salkind, MD                                                                              9/3/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Marital Trust GST Subject U/T/W of Leopold Salkind DTD 10/29/02, Marilyn Salkind,             9/4/2003       25,000
Gene Salkind, Trustees
--------------------------------------------------------------------------------------------------------------------
Peter Levitch                                                                                 9/5/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Steven R. Salovitch                                                                           9/5/2003       10,000
--------------------------------------------------------------------------------------------------------------------
Lisa Rachlin                                                                                  9/6/2003          500
--------------------------------------------------------------------------------------------------------------------
Schenk Family Trust/Carl Schenk Trustee                                                       9/7/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Chicago Private Investments, Inc.                                                             9/7/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Kanter Family Foundation                                                                     9/12/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Alan Sheinwald                                                                               9/15/2003       15,000
--------------------------------------------------------------------------------------------------------------------
Jay Silberman                                                                                9/15/2003       75,000
--------------------------------------------------------------------------------------------------------------------
David Wiener Revocable Trust -96                                                             9/15/2003      100,000
--------------------------------------------------------------------------------------------------------------------
Larry R. Rice                                                                                9/16/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Joseph Reynolds                                                                              9/17/2003       50,000
--------------------------------------------------------------------------------------------------------------------
HSB Capital                                                                                  9/18/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Andrew J. Maffey                                                                             9/19/2003       25,000
--------------------------------------------------------------------------------------------------------------------
Hans Gaverstroem                                                                             9/19/2003       20,000
--------------------------------------------------------------------------------------------------------------------
Angeliki Frangou                                                                             10/3/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Global eMedicine, Inc., MPPP                                                                 10/5/2003       50,000
--------------------------------------------------------------------------------------------------------------------
Anasazi Partners II, LLC                                                                    10/13/2003      100,000
--------------------------------------------------------------------------------------------------------------------
Anasazi Partners III LLC                                                                    10/21/2003      250,000
--------------------------------------------------------------------------------------------------------------------
Christopher P. Baker                                                                        11/13/2003      250,000
--------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-10EXHIBIT 4.21

THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED
PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT
AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION
THEREOF. NEITHER THIS WARRANT NOR SUCH SHARES (TOGETHER, THE "SECURITIES") HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY
STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH
DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE ACT AND OF ANY APPLICABLE STATE SECURITIES LAWS.

NO. WC-                                           ISSUED [SEE ATTACHED SCHEDULE]

                        WARRANT TO PURCHASE COMMON STOCK

                                   __________

      THIS CERTIFIES THAT, for good and valuable consideration, [SEE ATTACHED
SCHEDULE FOR NAMES OF HOLDERS] (the "HOLDER") is entitled to subscribe for and
purchase from Adventrx Pharmaceuticals, Inc., a Delaware corporation (the
"COMPANY"), [SEE ATTACHED SCHEDULE FOR NUMBER OF SHARES] fully paid and
nonassessable shares of Common Stock, par value $0.001 per share ("COMMON
STOCK"), of the Company (as adjusted pursuant to Section 3 hereof) (the "WARRANT
SHARES") at a price per share equal to One Dollar and Twenty Five Cents ($1.25)
(as adjusted pursuant to Section 3 hereof) (the "EXERCISE PRICE"), subject to
the provisions and upon the terms and conditions hereinafter set forth.

1.    METHOD OF EXERCISE; PAYMENT.

      (A) Exercise Period. The purchase rights represented by this Warrant may
be exercised by the Holder during the term of this Warrant (as set forth in
Section 9 hereof) in whole or in part, at any time after the Commencement Date,
as defined below, by the surrender of this Warrant (with the notice of exercise
form attached hereto as Exhibit A (the "NOTICE OF EXERCISE") duly executed) at
the principal office of the Company.

      (B) Cash Exercise. Upon exercise of this Warrant, the Holder shall pay the
Company an amount equal to the Exercise Price multiplied by the number of
Warrant Shares being purchased, by wire transfer or certified check payable to
the order of the Company. The person or persons in whose name(s) any
certificate(s) representing the Warrant Shares shall be issuable upon exercise
of this Warrant shall be deemed to have become the holder(s) of record of, and
shall be treated for all purposes as the record holder(s) of, the Warrant Shares
represented thereby (and such Warrant Shares shall be deemed to have been
issued) immediately prior to the close of business on the date or dates upon
which this Warrant is exercised.

                                       1
<PAGE>

      (C) Stock Certificates. In the event of any exercise of the rights
represented by this Warrant, certificates for the Warrant Shares so purchased
shall be delivered to the Holder within a reasonable time after exercise and,
unless this Warrant has been fully exercised or has expired, a new Warrant
representing the shares with respect to which this Warrant shall not have been
exercised shall also be issued to the Holder within such time.

2. STOCK FULLY PAID; RESERVATION OF SHARES. All of the Warrant Shares issuable
upon the exercise of the rights represented by this Warrant will, upon issuance
and receipt of the Exercise Price therefor, be fully paid and nonassessable, and
free from all preemptive rights, rights of first refusal or first offer, taxes,
liens and charges with respect to the issuance thereof. During the period within
which the rights represented by this Warrant may be exercised, the Company shall
at all times have authorized and reserved for issuance a sufficient number of
Warrant Shares to provide for the exercise of the rights represented by this
Warrant.

3. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES. The number and kind of
Warrant Shares purchasable upon the exercise of this Warrant and the Exercise
Price therefor shall be subject to adjustment from time to time upon the
occurrence of certain events, as follows:

      (A) Reclassification, Consolidation or Reorganization. In case of any
reclassification of the Common Stock (other than a change in par value, or as a
result of a subdivision or combination), or in case of any consolidation or
merger of the Company with or into another corporation (other than a Change of
Control, as defined below) (any of which is a "REORGANIZATION TRANSACTION"), the
Company, or such successor corporation as the case may be, shall execute a new
warrant, providing that the holder of this Warrant shall have the right to
exercise such new warrant, and procure upon such exercise and payment of the
same aggregate Exercise Price, in lieu of the Warrant Shares theretofore
issuable upon exercise of this Warrant, the kind and amount of shares of stock,
other securities, money and property as would be payable for the Warrant Shares
issuable upon exercise of this Warrant as if such Warrant Shares were
outstanding on the consummation of the Reorganization Transaction. For purposes
of this Warrant, the term "CHANGE OF CONTROL" shall mean (i) any acquisition of
the Company by means of merger, acquisition, or other form of corporate
reorganization in which outstanding shares of the Company are exchanged for
securities or other consideration issued, or caused to be issued, by the
acquiring corporation or its subsidiary or parent (other than a reincorporation
transaction or change of domicile) and pursuant to which the holders of the
outstanding voting securities of the Company immediately prior to such
consolidation, merger or other transaction fail to hold equity securities
representing a majority of the voting power of the Company or surviving entity
immediately following such consolidation, merger or other transaction (excluding
voting securities of the acquiring corporation held by such holders prior to
such transaction) or (ii) a sale of all or substantially all of the assets of
the Company.

      (B) Stock Splits, Dividends and Combinations. In the event that the
Company shall at any time subdivide the outstanding shares of Common Stock, or
shall issue a stock dividend on its outstanding shares of Common Stock, the
number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such subdivision or to the issuance of such stock dividend shall be
proportionately increased, and the Exercise Price shall be proportionately
decreased, and in the event that the Company shall at any time combine the
outstanding shares of Common Stock, the number of Warrant Shares issuable upon
exercise of this Warrant immediately prior to such combination shall be
proportionately decreased, and the Exercise Price shall be proportionately
increased, effective at the close of business on the date of such subdivision,
stock dividend or combination, as the case may be.

                                       2
<PAGE>

4. TRANSFER OF WARRANT. This Warrant may only be transferred in compliance with
federal and state securities laws and, except as provided below, may not be
transferred except with the prior written consent of the Company, which shall
not be unreasonably withheld or delayed, and any purported transfer without such
prior written consent shall be null and void; provided, however, that the
Company may withhold its consent to transfer or assignment of this Warrant to
any person or entity who is deemed to be a competitor or prospective competitor
of the Company, such determination to be made in the reasonable judgment of the
Board.

5. CONDITION TO EXERCISE OF WARRANT. Each certificate evidencing the Warrant
Shares issued upon exercise of this Warrant shall be stamped or imprinted with a
legend substantially in the following form:

      THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
      INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY
      DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
      ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS. SUCH
      SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
      THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO
      THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
      THE ACT OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.

6. FRACTIONAL SHARES. No fractional Warrant Shares will be issued in connection
with any exercise hereunder, but in lieu of such fractional shares the Company
shall make a cash payment therefor upon the basis of the Exercise Price then in
effect.

7. REPRESENTATIONS AND WARRANTIES BY THE HOLDER. The Holder represents and
warrants to the Company as follows:

      (A) This Warrant is being acquired for the Holder's own account, for
investment and not with a view to, or for resale in connection with, any
distribution or public offering thereof within the meaning of the Securities Act
of 1933, as amended (the "SECURITIES ACT"). Upon exercise of this Warrant, the
Holder shall, if so requested by the Company, confirm in writing, in a form
reasonably satisfactory to the Company, that the Warrant Shares issuable upon
exercise of this Warrant are being acquired for investment and not with a view
toward distribution or resale. The Holder is an "accredited investor" within the
meaning of the Securities Act.

      (B) The Holder understands that this Warrant and the Warrant Shares have
not been registered under the Securities Act by reason of their issuance in a
transaction exempt from the registration and prospectus delivery requirements of
the Securities Act pursuant to Section 4(2) thereof and that the Company's
reliance upon such exemption is predicated, in part, upon the Holder's
representations and warranties set forth in this Agreement. The Holder
understands that this Warrant and the Warrant Shares must be held by the Holder
indefinitely, and that the Holder must therefore bear the economic risk of such
investment indefinitely, unless a subsequent disposition thereof is registered
under the Securities Act or is exempted from such registration. The Holder
further understands that this Warrant and the Warrant Shares have not been
registered under the securities laws of any state.

                                       3
<PAGE>

      (C) The Holder acknowledges that it is acquiring this Warrant without
being offered or furnished any offering literature or prospectus. The Holder
understands that neither the United States Securities and Exchange Commission,
nor any governmental agency charged with the administration of the securities
laws of any state nor any other governmental agency has passed upon or reviewed
the merits or qualifications of, or recommended or approved the issuance of this
Warrant or the Warrant Shares.

      (D) The Holder understands that, except as provided in Section 10 of this
Warrant, the Company is under no obligation to register this Warrant or the
Warrant Shares.

      (E) The Holder is a bona fide resident and domiciliary (not a temporary or
transient resident) of the state indicated in the signature page hereto and the
Holder has no present intention of becoming a resident of any other state or
jurisdiction.

      (F) The Holder has such knowledge and experience in financial and business
matters that it is capable of evaluating the merits and risks of the purchase of
this Warrant and the Warrant Shares purchasable pursuant to the terms of this
Warrant and of protecting its interests in connection therewith. The Holder is
able to bear the economic risk of the purchase of the Warrant Shares pursuant to
the terms of this Warrant.

      (G) The Holder of this Warrant agrees not to undertake any short position
with respect to the underlying common stock while this warrant remains
outstanding.

8. RIGHTS OF STOCKHOLDERS. No holder of this Warrant shall be entitled, as a
Warrant holder, to vote or receive dividends or be deemed the holder of Warrant
Shares or any other securities of the Company which may at any time be issuable
on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon the Holder any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action (whether upon any recapitalization, issuance of stock,
reclassification of stock, change of par value, consolidation, merger,
conveyance, or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or otherwise with respect to the Warrant Shares
until this Warrant shall have been exercised and the Warrant Shares purchasable
upon the exercise hereof shall have become deliverable, as provided herein.

                                       4
<PAGE>

9.   TERM OF WARRANT.

      (A) This Warrant shall become exercisable on the date of issuance set
forth below (the "COMMENCEMENT DATE") and shall no longer be exercisable as of
the earlier of (i) 5:00 p.m., San Diego, California local time, on the date that
is the three-year anniversary of the Commencement Date; (ii) immediately prior
to a Change of Control and (iii) 5:00 p.m., San Diego, California local time, on
the Call Termination Date (as defined below).

      (B) Notwithstanding anything herein to the contrary, at any time after the
Commencement Date, if the closing price of one share of Common Stock quoted in
the over-the-counter market summary, the Bulletin Board Exchange, the Nasdaq
National Market or the closing price quoted on a national securities exchange,
whichever is applicable, is greater than 200% of the Exercise Price for a period
of 20 consecutive trading days, then thereafter the Company shall have the right
(the "COMPANY TERMINATION RIGHT"), exercisable at the Company's sole discretion,
to terminate this Warrant with at least 10-days' prior written notice (the
"TERMINATION NOTICE") which Termination Notice shall state the date this Warrant
shall terminate (the "CALL TERMINATION DATE"); provided, however, that the
Company may not exercise the Company Termination Right unless a registration
statement registering the Warrant Stock has been declared effective and is
effective from the date of delivery of the Termination Notice until the Call
Termination Date, provided, further, that if this Warrant is terminated pursuant
to this Section 9(b), then the Company shall use commercially reasonable efforts
to maintain the effectiveness of a registration statement registering the
Warrant Stock until the date that is 15 days after the Call Termination Date or,
if earlier, the date the Holder shall have sold all its Warrant Shares covered
by such registration statement.

10.  REGISTRATION RIGHTS.

      (A) Piggy-back Rights. If (but without any obligation to do so) the
Company proposes to register any shares of Common Stock solely for cash pursuant
to a registration statement under the Securities Act, other than a registration
solely in connection with a transaction under Rule 145 promulgated under the
Securities Act (a "PUBLIC OFFERING"), the Company shall promptly give the Holder
written notice of such Public Offering, at least 10 business days prior to the
filing of the registration statement under the Securities Act regarding such
Public Offering. Upon the written request of the Holder given within 5 business
days after delivery of such written notice by the Company, the Company shall,
subject to the provisions of Section 10(b) below, use its best efforts to cause
to be registered under the Securities Act all of the Warrant Shares that the
Holder has requested to be registered.

      (B) Underwriting. If the registration statement under which the Company
gives notice under this Section 10 is for an underwritten Public Offering, the
Company shall so advise the Holder. The right of the Holder to registration
pursuant to Section 10(a) above shall be conditioned upon the Holder's
participation in such underwriting and the inclusion of the Warrant Shares in
the underwriting to the extent provided herein. The Holder shall (together with
the Company and any other holders of Company securities distributing their
securities through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for underwriting by
the Company. Notwithstanding any other provision of this Section 10, if the
underwriter determines that marketing factors require a limitation of the number
of shares to be underwritten, the underwriter may exclude some or all of the
Warrant Shares from such registration and underwriting.

                                       5
<PAGE>

      (C) Furnish Information. It shall be a condition to the Company's
obligations to take any action under this Section 10 that the Holder shall
furnish to the Company such information regarding itself, the Warrant Shares,
and the intended method of disposition of such Warrant Shares as shall be
required to effect the registration of any Warrant Shares. In that connection,
the Holder shall be required to represent to the Company that all such
information which is given is both complete and accurate in all material
respects when made.

      (D) Delay of Registration. The Holder shall have no right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 10.

      (E) Termination of Registration Rights. The Company shall have no
obligation to register Warrant Shares pursuant to this Section 10 with respect
to any request or requests made by any Holder on or after that date which is one
year after the date such Warrant Shares were deemed to be acquired for purposes
of determining the holding period of such Warrant Shares under Rule 144 of the
Act.

11.  MISCELLANEOUS.

      (A) This Warrant is being delivered in the state of California and shall
be construed and enforced in accordance with and governed by the laws of the
state of California, without giving effect to principles of conflicts of laws.

      (B) The headings in this Warrant are for purposes of reference only, and
shall not limit or otherwise affect any of the terms hereof.

      (C) The terms of this Warrant shall be binding upon and shall inure to the
benefit of any successors or assigns of the Company and of the Holder and of the
Warrant Shares issued or issuable upon the exercise hereof.

      (D) Any notice provided for or permitted under this Warrant shall be
treated as having been given (a) upon receipt, when delivered personally, (b)
upon receipt, when sent by confirmed facsimile or telecopy, (c) one day after
sending, when sent by commercial overnight courier with written verification of
receipt, or (d) three business days after deposit with the United States Postal
Service, when mailed postage prepaid by certified or registered mail, return
receipt requested, addressed (a) if to the Company, at 9948 Hibert Street, Suite
100, San Diego, CA 92131, facsimile: (858) 271-9678, Attention: Nicholas J.
Virca, or (b) if to the Holder, at such address or facsimile number as the
Holder shall have furnished to the Company in writing, or at such other place of
which the other party has been notified in accordance with the provisions of
this Section 11(d).

      (E) This Warrant constitutes the full and entire understanding and
agreement between the parties with regard to the subjects hereof.

                                       6
<PAGE>

      (F) Upon receipt of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant and, in the case of any
such loss, theft or destruction, upon delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in the case of any
such mutilation, upon surrender and cancellation of such Warrant, the Company at
the Holder's expense will execute and deliver to the holder of record, in lieu
thereof, a new Warrant of like date and tenor.

      (G) This Warrant and any provision hereof may be amended, waived or
terminated only by an instrument in writing signed by the Company and the
Holder.

      (H) Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to the foregoing terms and conditions.

                            [Signature page follows.]

                                       7
<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its duly authorized officer.

         Issued :[SEE ATTACHED SCHEDULE]

                               ADVENTRX PHARMACEUTICALS, INC.

                               By:      /s/ Nicholas J. Virca

                               Name:    Nicholas J. Virca

                               Title:   President and Chief Executive Officer

                               [SEE ATTACHED SCHEDULE]

                               By:      _______________________________________

                               Name:    _______________________________________

                               Title:   _______________________________________

                               Address:   _____________________________________

                                          _____________________________________

                               Facsimile: _____________________________________

                                       8
<PAGE>

                                    EXHIBIT A

                               NOTICE OF EXERCISE

TO:      Adventrx Pharmaceuticals, Inc.
         9948 Hibert Street, Suite 100
         San Diego, CA  92131

      The undersigned hereby elects to purchase ____________ shares of Common
Stock, par value $0.001 per share, of the Company ("COMMON STOCK") pursuant to
the terms of Section 1(b) of the Warrant to Purchase Common Stock dated
___________ 2003 (the "WARRANT"), and tenders herewith payment of the purchase
price of such shares in full.

      Please issue a certificate or certificates representing said _________
shares of Common Stock in the name of the undersigned or in such other name as
is specified below:

                           Name:      _________________________________

                           Address:   _________________________________

                                      _________________________________

      The undersigned hereby represents and warrants that the aforesaid shares
of Common Stock are being acquired for the account of the undersigned for
investment and not with a view to, or for resale, in connection with the
distribution thereof, and that the undersigned has no present intention of
distributing or reselling such shares, and that all representations and
warranties of the undersigned set forth in Section 7 of the Warrant are true and
correct as of the date hereof.

                                      ______________

                                      By:      ________________________________

                                      Name:    ________________________________

                                      Title:   ________________________________

                                      Date:    ________________________________

                                       9
<PAGE>

                           SCHEDULE OF WARRANTHOLDERS

      ADVENTRX Pharmaceuticals, Inc. issued this form of Warrant to Purchase
Common Stock to each of the persons listed below on the dates set forth below
for the purchase of up to the number of shares of Common Stock listed opposite
such person's name below.

<TABLE>
<CAPTION>

HOLDER                                                                WARRANT NO.       ISSUE DATE       SHARES
--------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>         <C>               <C>
Ball Family Trust (Edward D. Ball and Susan E. Ball, Trustees)           WC-201         10/15/2003         30,000
--------------------------------------------------------------------------------------------------------------------
Benjamin Partners Savings Plan FBO Jeffrey Benison                       WC-202         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Botka-Liu Family Revocable Trust, Dated 8/10/2000                        WC-203         10/15/2003          6,000
--------------------------------------------------------------------------------------------------------------------
David and Jennifer Brown                                                 WC-204         10/15/2003            150
--------------------------------------------------------------------------------------------------------------------
John R. and Marjorie B. Brown                                            WC-205         10/15/2003            600
--------------------------------------------------------------------------------------------------------------------
BSI-New Biomedical Frontier (Sicav)                                      WC-206         10/15/2003        150,000
--------------------------------------------------------------------------------------------------------------------
Bullbear Capital Partners, LLC                                           WC-207         10/15/2003         37,500
--------------------------------------------------------------------------------------------------------------------
Sean M. Callahan                                                         WC-208         10/15/2003          4,500
--------------------------------------------------------------------------------------------------------------------
Peter J. and Elaine Chortek, Trustees of the Peter J. and Elaine
Chortek Restarted Family Trust, Dated January 24, 1994 as Amended
and restarted                                                            WC-209         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Charles and Leslie Close                                                 WC-210         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Chicago Private Investments, Inc.                                        WC-211         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Clariden Investments, LTD.                                               WC-212         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Deborah Young, M.D. APC Employees Retirement Trust Y/A DTD 4/2/91        WC-213         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Elaine Dines                                                             WC-214         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Michael Elconin                                                          WC-215         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Jurg Fluck                                                               WC-216         10/15/2003          2,700
--------------------------------------------------------------------------------------------------------------------
Mark A. Ford                                                             WC-217         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Hans Gaverstroem                                                         WC-218         10/15/2003          6,000
--------------------------------------------------------------------------------------------------------------------
Michael M. Goldberg                                                      WC-219         10/15/2003          6,000
--------------------------------------------------------------------------------------------------------------------
Roland Hartmann                                                          WC-220         10/15/2003          6,000
--------------------------------------------------------------------------------------------------------------------
Haywood Securities Inc in Trust for Bridge Finance Ltd.                  WC-221         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Brian M. Herman                                                          WC-222         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Jeff Hermanson                                                           WC-223         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Kantor Family Foundation                                                 WC-224         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Dannie King                                                              WC-225         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
John J. Kissane                                                          WC-226         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Michael Kooper                                                           WC-227         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Jay S. and Gabrielle Kunin                                               WC-228         10/15/2003          4,500
--------------------------------------------------------------------------------------------------------------------
James Ladner                                                             WC-229         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Craig Langweiler                                                         WC-230         10/15/2003            900
--------------------------------------------------------------------------------------------------------------------
Peter Levitch                                                            WC-231         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Marital Trust GST Subject U/T/W of Leopold Salkind DTD 10/29/02,         WC-232         10/15/2003          7,500
Marilyn Salkind, Gene Salkind, Trustees

</TABLE>

                                       10
<PAGE>

<TABLE>
<CAPTION>

--------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>         <C>               <C>
David W. Penney & Sarah B. McAllister                                    WC-233         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Deborah Melnick                                                          WC-234         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Robert A. Melnick                                                        WC-235         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Paul Mezei                                                               WC-236         10/15/2003            600
--------------------------------------------------------------------------------------------------------------------
Robert J. Neborsky, M.D., Inc. Combination Retirement Trust              WC-237         10/15/2003         37,500
--------------------------------------------------------------------------------------------------------------------
William B. Newman                                                        WC-238         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Emanuel Peluso                                                           WC-239         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Lisa Rachlin                                                             WC-240         10/15/2003            150
--------------------------------------------------------------------------------------------------------------------
Mark Eugene Reaman                                                       WC-241         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Joseph Reynolds                                                          WC-242         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Larry R. Rice                                                            WC-243         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Gene Salkind, M.D.                                                       WC-244         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Steven R. Salovitch                                                      WC-245         10/15/2003          3,000
--------------------------------------------------------------------------------------------------------------------
Schenk Family Trust/Carl Schenk Trustee                                  WC-246         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Schroder & Co Bank AG                                                    WC-247         10/15/2003         45,000
--------------------------------------------------------------------------------------------------------------------
SDS Merchant Fund, L.P.                                                  WC-248         10/15/2003         75,000
--------------------------------------------------------------------------------------------------------------------
Eugene H. Seymour, M.D.                                                  WC-249         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Alan Sheinwald                                                           WC-250         10/15/2003          4,500
--------------------------------------------------------------------------------------------------------------------
Jay Silberman                                                            WC-251         10/15/2003         22,500
--------------------------------------------------------------------------------------------------------------------
Eric T. Singer                                                           WC-252         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
David Wiener, Revocable Trust-96                                         WC-253         10/15/2003         30,000
--------------------------------------------------------------------------------------------------------------------
Sandi Yurichuk                                                           WC-254         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
HSB Capital                                                              WC-255         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Andrew J. Maffey                                                         WC-256         10/15/2003          7,500
--------------------------------------------------------------------------------------------------------------------
Angelika Frangou                                                         WC-258         10/15/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Richard Melnick                                                          WC-260         10/15/2003         16,000
--------------------------------------------------------------------------------------------------------------------
P Bioventures LLC                                                       WC-261         10/15/2003         21,750
--------------------------------------------------------------------------------------------------------------------
Michael Gottlieb                                                         WC-262         10/15/2003         12,500
--------------------------------------------------------------------------------------------------------------------
Robert Nathan                                                            WC-264         10/15/2003          7,525
--------------------------------------------------------------------------------------------------------------------
HC Wainwright                                                            WC-265         10/15/2003          3,225
--------------------------------------------------------------------------------------------------------------------
Brian Corday                                                             WC-266         10/15/2003          3,125
--------------------------------------------------------------------------------------------------------------------
Ernst Pernet                                                             WC-267         10/15/2003         15,450
--------------------------------------------------------------------------------------------------------------------
Christopher P. Baker                                                     WC-268         12/15/2003         75,000
--------------------------------------------------------------------------------------------------------------------
Anasazi Partners III, LLC                                                WC-269         12/15/2003         75,000
--------------------------------------------------------------------------------------------------------------------
Anasazi Partners II, LLC                                                 WC-270         12/15/2003         30,000
--------------------------------------------------------------------------------------------------------------------
Pali Capital, LLC                                                        WC-271         12/15/2003          4,462
--------------------------------------------------------------------------------------------------------------------
Mathew Balk                                                              WC-272         12/15/2003         20,081
--------------------------------------------------------------------------------------------------------------------
Burnham Hill Holdings, LLC                                               WC-273         12/15/2003         20,082
--------------------------------------------------------------------------------------------------------------------
Craig Pierson                                                            WC-274          12/4/2003         67,500
--------------------------------------------------------------------------------------------------------------------
Michael Gottlieb                                                         WC-275          12/4/2003         67,500
--------------------------------------------------------------------------------------------------------------------
Benny Daniels                                                            WC-276          12/4/2003         15,000
--------------------------------------------------------------------------------------------------------------------
Schroder & Co. Bank AG, Zurich                                           WC-277         12/15/2003        240,000
--------------------------------------------------------------------------------------------------------------------
Clariden Investments, LTD.                                               WC-278         12/15/2003          6,000
--------------------------------------------------------------------------------------------------------------------
Peter Levitch                                                            WC-279         12/15/2003          9,000
--------------------------------------------------------------------------------------------------------------------
Bridge Finance, LTD                                                      WC-280         12/29/2003         61,500
--------------------------------------------------------------------------------------------------------------------
VP Bioventures, LLC                                                      WC-281         12/29/2003          2,250
--------------------------------------------------------------------------------------------------------------------

</TABLE>

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]